The anti-CD4CAR LVs in the current study recognized specifically CD8 as target receptor and allowed the generation of CD4-directed CAR CD8 T cells in vivo, which eliminated CD4 + malignant T cells in a primary murine AITL lymphoma. The gene discussed is CD8A; the disease is lymphoma.